1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Iron Deficiency Anemia - Pipeline Review, H1 2017

Iron Deficiency Anemia - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 76 pages

Iron Deficiency Anemia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia – Pipeline Review, H1 2017, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 3, 1, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Iron Deficiency Anemia - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Iron Deficiency Anemia - Overview
Iron Deficiency Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Iron Deficiency Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iron Deficiency Anemia - Companies Involved in Therapeutics Development
Galenica Ltd
Johnson and Johnson
Novartis AG
Panion and Bf Biotech Inc
Pieris Pharmaceuticals Inc
Rockwell Medical Inc
Shield Therapeutics Plc
Iron Deficiency Anemia - Drug Profiles
CSJ-137 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Drug to Replace Iron for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ferric maltol - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ferric pyrophosphate citrate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
JNJ-42905343 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NSC-8679 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
PRS-080 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
PT-30 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Iron Deficiency Anemia - Dormant Projects
Iron Deficiency Anemia - Product Development Milestones
Featured News and Press Releases
Jan 12, 2017: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology
Jan 08, 2017: Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference
Jan 06, 2017: Shield Therapeutics Provides Business Update
Dec 07, 2016: EFFECT-HF demonstrates a significantly beneficial effect of Ferinject on exercise capacity among patients with chronic heart failure and iron deficiency - confirms findings of previous studies
Nov 17, 2016: Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
Sep 07, 2016: Shield Therapeutics Announces Composition of Matter Patent Granted on Feraccru
Jun 17, 2016: Feraccru (ferric maltol) launched in the UK for the treatment of adults with iron deficiency anemia in patients with inflammatory bowel disease
Apr 28, 2016: Rockwell Medical Announces Triferic Presentation "Overcoming Functional Iron Deficiency in Your Hemodialysis Patients" at the National Kidney Foundation (NKF) Spring Clinical Meeting in Boston
Mar 29, 2016: Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease
Mar 21, 2016: China FDA Accepts Rockwell Medical's Triferic Drug Submission for Commercialization in China
Feb 26, 2016: Feraccru receives marketing authorisation in Europe
Feb 22, 2016: Rockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia
Jan 19, 2016: Rockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 - May 1, 2016 in Boston, MA
Dec 18, 2015: Shield Therapeutics announces receipt of a positive opinion from the CHMP recommending the approval of Feraccru for the treatment of iron deficiency anemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Iron Deficiency Anemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Iron Deficiency Anemia - Pipeline by Galenica Ltd, H1 2017
Iron Deficiency Anemia - Pipeline by Johnson and Johnson, H1 2017
Iron Deficiency Anemia - Pipeline by Novartis AG, H1 2017
Iron Deficiency Anemia - Pipeline by Panion and Bf Biotech Inc, H1 2017
Iron Deficiency Anemia - Pipeline by Pieris Pharmaceuticals Inc, H1 2017
Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, H1 2017
Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, H1 2017
Iron Deficiency Anemia - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Iron Deficiency Anemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) - Pipeline Review, H2 2016

Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase ...

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2016

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis I (MPS ...

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2016

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.